NASDAQ$ANGO

AngioDynamics Inc · Q3 2022 earnings

Q3 2022 earnings · · Investor relations

Briefing

AngioDynamics' Q3 2022 financial results were announced, showing a slight increase in net sales despite facing macroeconomic headwinds.

AngioDynamics reported a 3.9% increase in net sales for the third quarter of fiscal year 2022, reaching $74.0 million. Med Tech sales grew by 28.6%, while Med Device sales declined by 2.8%. The company experienced a net loss of $5.0 million, or $0.13 per share, but adjusted earnings per share were $0.03. Gross margin was 52.2%, impacted by supply chain disruptions, procedural challenges, and inflation. The company reaffirmed its fiscal year 2022 guidance.

  • Net sales increased by 3.9% to $74.0 million compared to the prior-year quarter.
  • Med Tech sales grew by 28.6%, while Med Device sales decreased by 2.8% year over year.
  • Gross margin was 52.2%, a decrease of 190 basis points year over year.
  • The company reaffirms fiscal year 2022 guidance.

Headline financials

Total Revenue

$74M

Previous: $71.2M+3.9%
EPS (adj)

$0.03

Previous: $0.02+50.0%
Gross Margin

52.2%

Previous: 54.1%-3.5%
Capital Expenditures

-$3.26M

Previous: -$4.57M+28.7%
Free Cash Flow

-$8.22M

Previous: -$8.11M-1.3%
Net Income

-$4.96M

Previous: -$3.54M-39.9%
Operating Income

-$5.3M

Previous: -$3.74M-41.7%
Gross Profit

$38.6M

Previous: $38.5M+0.1%
Cash & Equivalents

$23.9M

Previous: $54.5M-56.1%
Total Assets

$543M

Previous: $582M-6.7%
Stock-Based Comp

$2.35M

Previous: $2.15M+9.5%

Revenue & EPS history

AngioDynamics · Revenue · Quarterly

$74M

Q3 2022+3.9%vs Q3 2021
Beat estimate in 9 of 16 quarters(56%)
ActualEstimate

Revenue by segment

AngioDynamics · $74M total across 2 segments · Q3 2022

  • Med Device
    $54.4M
  • Med Tech
    $19.6M

Forward guidance

The Company continues to expect: Fiscal year 2022 net sales to be in the range of $310 to $315 million; Gross margin to be in the range of 52.0% to 54.0%; and Adjusted earnings per share in the range of a loss of $0.02 to a gain of $0.02.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q3 2022

Historical avgQ3 2022

-0.9%

Avg return

Earnings day

-2.4%

Avg return

5 days after

-3.7%

Avg return

30 days after

43%

28 / 65 earnings

Positive

+30.9%

Q2 2025

Best reaction

-26.2%

Q1 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2026+5.0%-5.0%
Q2 2026-13.5%-25.5%-24.0%
Q1 2026+6.1%-0.2%+8.7%
Q4 2025-10.2%-9.8%-9.3%
Q3 2025+12.4%-3.6%-3.8%
Q2 2025+30.9%+32.6%+17.4%
Q1 2025-20.3%-23.1%-12.7%
Q4 2024+24.8%+21.1%+25.8%
Q3 2024+15.6%+14.6%+3.1%
Q2 2024-17.7%-20.1%-23.5%
Q1 2024-5.9%-7.2%-10.4%
Q4 2023-2.5%-3.8%-16.1%
Q3 2023-17.1%-23.3%-33.3%
Q2 2023+11.5%-1.0%-1.3%
Q1 2023-26.2%-38.0%-34.8%
Q4 2022+4.4%+6.4%+21.3%
Q3 2022+9.8%+7.2%-8.7%
Q2 2022-15.5%-15.5%-25.8%
Q1 2022+12.6%+17.8%+22.4%
Q4 2021-7.0%-8.6%-3.9%
Q3 2021+12.3%+11.1%+16.3%
Q2 2021+14.7%+14.2%+24.7%
Q1 2021+13.0%+7.8%-0.1%
Q4 2020-11.5%-11.8%-12.7%
Q3 2020-2.7%+2.3%-0.6%
Q2 2020-9.2%-11.3%-17.0%
Q1 2020-17.6%-17.6%-13.7%
Q4 2019+6.8%+6.2%-4.8%
Q3 2019-7.7%-8.2%-18.4%
Q2 2019+6.7%+6.7%+8.6%
Q1 2019-10.3%-12.9%-17.0%
Q4 2018-9.2%-7.8%-5.4%
Q3 2018+3.2%+8.9%+16.4%
Q2 2018-1.8%-0.1%+5.1%
Q1 2018-8.9%-9.1%-8.4%
Q4 2017-5.9%-3.5%+5.1%
Q3 2017+0.3%-1.3%-10.2%
Q2 2017+1.7%+3.2%-2.5%
Q1 2017-4.5%-0.1%-8.4%
Q4 2016+10.6%+14.1%+8.4%
Q3 2016-2.1%
Q2 2016-8.7%
Q1 2016-8.8%
Q4 2015-2.3%
Q3 2015-6.1%
Q2 2015-0.9%
Q1 2015+3.8%
Q4 2014-5.0%
Q3 2014-1.5%
Q2 2014+6.1%
Q1 2014+5.3%
Q4 2013+1.3%
Q3 2013-7.4%
Q2 2013-2.4%
Q1 2013-8.8%
Q4 2010-0.9%
Q4 2012+4.0%
Q3 2011-1.3%
Q3 2012-1.3%
Q2 2012-5.7%
Q2 2011-5.7%
Q1 2011+3.5%
Q4 2011+3.5%
Q1 2012+3.5%
Q3 2010+0.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro